We are live on ! Find out more
RXST icon

RxSight

192 hedge funds and large institutions have $923M invested in RxSight in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 94 increasing their positions, 48 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,444% more call options, than puts

Call options by funds: $8.04M | Put options by funds: $227K

96% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 48

2.67% more ownership

Funds ownership: 87.65%90.32% (+2.7%)

9% less funds holding

Funds holding: 212192 (-20)

24% less capital invested

Capital invested by funds: $1.21B → $923M (-$291M)

45% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 42

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
192
Holders Change
-20
Holders Change %
-9.43%
% of All Funds
2.57%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
23
Increased
94
Reduced
48
Closed
42
Calls
$8.04M
Puts
$227K
Net Calls
+$7.82M
Net Calls Change
-$10.2M

RXST Hedge Fund Activity: Q1 2025 in Review

192 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q1 2025, worth a combined $923M — down 24% from $1.21B a quarter earlier.

Sellers outnumbered buyers: 42 funds closed out of RXST and 23 opened new positions — a net loss of 19 holders — while 48 trimmed existing stakes and 94 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $19.2M. The largest seller was Citadel Advisors, cutting an estimated $22.7M.

  • 192 institutional investors held RxSight (RXST) as of Q1 2025, down from 212 in Q4 2024.
  • Funds reported $923M of RxSight stock for Q1 2025, down 24% quarter-over-quarter.
  • 23 funds opened new RxSight positions in Q1 2025 and 42 closed out, a net change of -19 holders.
  • The largest RxSight buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $19.2M added.
  • The largest RxSight seller in Q1 2025 was Citadel Advisors, an estimated $22.7M sold.

Based on aggregated 13F filings for Q1 2025.